Companies Cryptocurrencies
Brickell Biotech Inc
Brickell Biotech Inc
Exchange: NasdaqCM
IPO Date: 10/03/1993
CEO: Mr. Robert Brown
Biotechnology Healthcare đź”—
  • BBI
  • 0.5529
  • 47502628
    market cap
  • -0.00309998
If you bought

shares of Brickell Biotech Inc (BBI) on
You would have made
Old Price $12 Current Price $12

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 30 full-time employees. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.

Address: 5777 Central Ave Ste 102 Boulder COLORADO 80301

Stay updated.